NetworkNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Adds Novel Molecule to Family of Psilocin Analogs
Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, has included a novel molecule — MYCO-005 — which has potential for heart-safe microdose enabling properties, to its psilocin analogs. The company submitted a patent application covering multiple families of psilocin analogs late last year, noting that these second-generation molecules address delivery and stability concerns with the first-generation compounds. According to the company, its research findings show the potential for a psilocin analog that may be considered a heart-safe microdose drug, which is a substance consumed at a low enough dose to provide benefits without inducing a psychoactive experience. Mydecine intends to continue to research this new feature set as it also studies its patent-pending, skin-permeation technology to produce a low-dosed, time-released patch drug that is non-hallucinatory. “When you consider any drug intended to be taken over a long period of time, there is often a strong medical risk involved,” said Mydecine chief scientific officer Rob Roscow in the press release. “When it comes to psilocybin in particular, there are cardiovascular health concerns due to the binding affinity to the 5-HT2B receptor. Through our ongoing research, we have found that one of our psilocin analogs is showing strong binding at the classic psychedelic 5-HT2A receptor but is not binding to the 5-HT2B receptor. This is a strong indication that our improved psilocin analog could potentially produce the same benefits of natural psilocybin with an increased safety profile for microdosing.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, has included a novel molecule — MYCO-005 — which has potential for heart-safe microdose enabling properties, to its psilocin analogs. The company submitted a patent application covering multiple families of psilocin analogs late last year, noting that these second-generation molecules address delivery and stability concerns with the first-generation compounds. According to the company, its research findings show the potential for a psilocin analog that may be considered a heart-safe microdose drug, which is a substance consumed at a low enough dose to provide benefits without inducing a psychoactive experience. Mydecine intends to continue to research this new feature set as it also studies its patent-pending, skin-permeation technology to produce a low-dosed, time-released patch drug that is non-hallucinatory. “When you consider any drug intended to be taken over a long period of time, there is often a strong medical risk involved,” said Mydecine chief scientific officer Rob Roscow in the press release. “When it comes to psilocybin in particular, there are cardiovascular health concerns due to the binding affinity to the 5-HT2B receptor. Through our ongoing research, we have found that one of our psilocin analogs is showing strong binding at the classic psychedelic 5-HT2A receptor but is not binding to the 5-HT2B receptor. This is a strong indication that our improved psilocin analog could potentially produce the same benefits of natural psilocybin with an increased safety profile for microdosing.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
